HIGHLIGHTS
- who: Kai Ding from the Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People`s Republic of China have published the paper: Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients, in the Journal: (JOURNAL) of 11/09/2022
- what: The authors report two myelofibrosis (MF) cases with continuously transfusion-dependent anemia after ruxolitinib treatment, which was corrected by roxadustat (FG-4592), a novel, orally bioavailable, heterocyclic small_molecule that reversibly inhibits hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzymes and activates HIF and the transcription of HIF-responsive genes . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.